Kornimate/medical-research-clean huggingface dataset:
women's antioxidant and folic acid cardiovascular study (wafacs)

Conditions: Cardiovascular Diseases; Coronary Arteriosclerosis; Coronary Disease; Heart Diseases; Myocardial Infarction; Myocardial Ischemia

Summary: to determine if supplements of vitamin c, vitamin e, beta-carotene, and b-vitamins (a combination of folic acid, vitamins b6 and b12) reduce risk of major cardiovascular events in high risk women with a prior history of atherosclerotic cardiovascular disease. the trial is a companion to the women's health study (whs), a primary prevention trial of vitamin e and aspirin in a low risk population of women.

the women's antioxidant and folic acid cardiovascular study tested the effects of vitamin c (500 mg/day), vitamin e (600 iu every other day), and/or beta carotene (50 mg every other day) on the risk of major cardiovascular events (a combined outcome of myocardial infarction, stroke, coronary revascularization, or cardiovascular death) among 8171 female health professionals at increased risk. participants were 40 years or older with a history of cardiovascular disease or 3 or more cardiovascular risk factors and were followed for an average duration of 9.4 years, from 1995-1996 to 2005. in 1998, 5442 of these participants were further randomized to the b-vitamin intervention (a daily combination pill containing folic acid \[2.5 mg\], vitamin b6 \[50 mg\], vitamin b12 \[1 mg\]) and were followed for 7.3 years, from april 1998 through july 2005.

Eligibility criteria:
women, aged 40 and over, at high risk, with a history of cardiovascular disease or three or more coronary heart disease risk factors.
prevalence and impact of sarcopenia in patients with inflammatory bowel disease

Conditions: Inflammatory Bowel Diseases; Sarcopenia

Summary: sarcopenia is a condition characterized by significant muscle loss resulting in impaired muscle function. this condition is likely associated with a biological deviation leading to reduced reserves to withstand stressors, resulting in a poorer prognosis. the incidence of sarcopenia among patients with inflammatory bowel diseases (ulcerative colitis and crohn's disease) is currently approximately 40-60%. this is likely a consequence of the preference for drug treatment over surgery, while many patients have continuous inflammation in their intestines leading to muscle loss and subsequently increased morbidity and mortality. the purpose of the study is to identify the prevalence of sarcopenia among patients experiencing a severe flare-up of their bowel disease and to evaluate whether the removal of the colon results in improved nutritional status. furthermore, the investigators aim to investigate whether there is a specific microbiota composition related to an unfavorable course. the participants are longitudinally monitored with measurements taken at the flare-up/before surgery and one year afterward, including body composition, function, dietary recording, quality of life, blood tests, fecal samples, and intestinal biopsies that will be analyzed. the investigators plan to correlate body composition with a biological profile and then evaluate if there is an association. additionally, the investigators aim to analyze if these markers are linked to different outcomes after colectomy. this study will contribute to an enhanced understanding of patients with advanced ibd and possibly change the perspective on how the clinicians should prioritize these patients for surgery. the investigators believe this study will lead to an improvement in healthcare quality and an enhanced understanding of how these disease processes function.

all examinations and laboratory tests will be conducted on two occasions. moreover, two cohorts will be present. that is, one group where participants experiencing a severe flare-up receive medical treatment, and another group where participants with the bowel disease undergo surgery. all samples/examinations and surveys are therefore done before the operation/during the flare-up, and then again one year later during a follow-up assessment

Eligibility criteria:
inclusion criteria: * all adult patients experiencing an acute flare-up of their bowel disease (ulcerative colitis or crohn's disease) admitted to a hospital in the region västra götaland and stockholm are invited to participate in the study. exclusion criteria: * not wishing to participate in the study inability to understand the language or study procedures

Keywords: sarcopenia
the effect of acupressure and yoga on premenstrual symptoms and quality of life

Conditions: Premenstrual Syndrome; Nursing Caries

Summary: the research was carried out to determine the effect of acupressure and yoga applied to cope with pms on premenstrual symptoms and quality of life.


Eligibility criteria:
inclusion criteria: * have regular menstrual cycle exclusion criteria: * has a psychiatric diagnosis, * having any gynecological disease (anornal uterine bleeding, fibroids, ovarian cyst etc.) * using contraceptive drugs, * with tissue deformity in its extremities, any health problems that may prevent physical exercise

Keywords: pms, yoga nursing health quality
a study of ly3314814 in participants with liver impairment

Conditions: Hepatic Impairment

Summary: the purpose of the study is to determine whether ly3314814 can be safely prescribed in participants with liver impairment without a dose adjustment. participants will be on study for 11 days with follow-up about 7 days afterward.


Eligibility criteria:
inclusion criteria: - have a body mass index (bmi) of 18 to 40 kilogram per meter square (kg/m²), inclusive, at the time of screening exclusion criteria: * have a history of or current significant ophthalmic disease, particularly any eye problem involving the retina * have moderate or severe vitiligo or any other clinically significant disorder of skin or hair pigmentation * have acute unstable neuropsychiatric disease * have active or uncontrolled neurologic disease, or clinically significant head injury
anti-thymocyte globulin and cyclosporine as first-line therapy in treating patients with severe aplastic anemia

Conditions: Aplastic Anemia

Summary: rationale: immunosuppressive therapies, such as anti-thymocyte globulin and cyclosporine, may improve bone marrow function and increase blood cell counts. purpose: this phase ii trial is studying how well giving anti-thymocyte globulin together with cyclosporine as first-line therapy works in treating patients with severe aplastic anemia.

primary objectives: to determine the response rate of r-atg and csa in the first line setting. secondary objectives: to determine the level of is as assessed by immuknow assay in responders and compare it to non-responders. outline:patients receive anti-thymocyte globulin iv over 4-24 hours daily on days 1-5. beginning on day 6, patients receive oral cyclosporine twice daily for 6 months followed by a taper. treatment continues in the absence of disease progression or unacceptable toxicity.

Eligibility criteria:
inclusion criteria: * all patients with saa as defined by camitta who are candidates for is therapy; these criteria include bone marrow cellularity \< 25% or 25-50% with \< 30% of hematopoietic cells; it should also have two of the following three parameters: peripheral blood neutrophils \< 0.5 x 10\^9/l, platelets \< 20 x 10\^9/l and reticulocytes \< 60 x 10\^9/l in anemic patients * if cytogenetic testing has been done, it should show normal karyotype or be not informative * patients should be either unwilling or otherwise ineligible (age, comorbidities, lack of donor) for bone marrow transplantation as a therapeutic modality * not previously treated with atg for saa * patients must have ecog performance status of 0, 1, or 2 * vitamin b12 and folic acid deficiency must be ruled out by measurement of serum levels * patients must have had a bone marrow biopsy examination in the three months prior to enrolling in the study * must be able to provide informed consent * systemic and other hematologic causes of pancytopenia, based on clinical presentation, must have been ruled out exclusion criteria: * patients with clinically evident congestive heart failure, serious cardiac arrhythmias; symptoms of coronary artery disease must be cleared by cardiology prior to therapy * patients who have had chemotherapy, radiotherapy, or immunotherapy or other investigational drug use within 3 weeks prior to study entry * pregnant women * all females of childbearing potential must have a blood test or urine study within two weeks prior to induction registration to rule out pregnancy * women of childbearing potential are strongly advised to use an accepted and effective method of contraception * patients who have medical, psychological, or social conditions that may interfere with the patient's participation in the study or evaluation of the study results
association between hepatitis c virus infection and hematologic and thyroid cancers

Conditions: Hepatitis C Virus

Summary: this study will investigate the possible relationship between infection with hepatitis c virus (hcv) and the development of certain hematologic cancers (non-hodgkin's lymphoma, hodgkin's lymphoma, chronic lymphocytic leukemia, multiple myeloma) and thyroid cancer. hcv causes chronic hepatitis, cirrhosis, and liver cancer. it is transmitted primarily through injection drug use and transfusion of infected blood. studies have shown that hcv may also be linked to hematologic cancers and thyroid cancer. this retrospective study will examine medical records from veterans with and without hcv infection who previously received treatment in the veterans administration medical system. data collected on each subject will include the subject's race, sex, age and era of military service, presence of liver disease or thyroiditis at their baseline clinic visit, number of inpatient visits in the past 5 years and outpatient visits in the past year, and the presence of various specified cancers. the prevalence of cancer and other conditions among hcv-infected subjects and non-hcv infected subjects at baseline and the subsequent development of the cancers of interest in these two groups will be compared and analyzed for a possible causal relationship.

hepatitis c virus (hcv) may be a cause of hematologic malignancies and thyroid cancer. hcv infection is common among u.s. military veterans receiving care in the veterans administration healthcare system. the investigators propose a retrospective cohort study using va administrative databases. a cohort of approximately 147,000 hcv-infected veterans has been identified for the period 1997-2004. likewise, a cohort of approximately 573,000 hcv-uninfected veterans has been identified for the same period. these subjects are being evaluated for the diagnosis of hematologic malignancies, thyroid cancer, and related medical conditions as recorded in va databases. the comparison of the prevalence and incidence of these cancers in the two cohorts will provide a test of the hypothesis that hcv infection can cause these cancers. the investigators will also evaluate the association between hcv infection and several other medical conditions, which might be related to hcv infection, specifically: immune thrombocytopenic purpura, autoimmune hemolytic anemia, cholangiocarcinoma, cholangitis, and pancreatic cancer.

Eligibility criteria:
* none given.

Keywords: lymphoma multiple myeloma thyroiditis cohort study record linkage study hepatitis c
heat loss prevention in very preterm infants in delivery rooms: a multicenter, randomized, controlled trial of polyethylene occlusive total body skin wrapping

Conditions: Hypothermia; Preterm Infant

Summary: hypothermia after delivery is a world-wide problem associated with morbidity and mortality. the conventional approach of drying the baby with a pre-warmed towel and radiant warmers is unsuccessful in a large proportion of very preterm infants. polyethylene occlusive skin wrapping covering the infant's body up to the neck will reduce postnatal heat loss in very preterm babies and represents the standard of care recommended by the international guidelines for neonatal resuscitation. the use of a polyethylene head cap will also reduce heat loss 9 and its efficacy is comparable to that obtained with the wrap. however, the proportions of hypothermic infants at nicu admission (temperature \<34°c) in the wrapped group (62%) as well as in the infants covered with a polyethylene cap (43%) remain high. the combination of body and head protection with a polyethylene wrap needs to be evaluated further. the investigators conducted a prospective, randomized, controlled trial in very preterm infants to evaluate whether a polyethylene total body wrapping (body plus head) prevents heat loss after delivery better than polyethylene occlusive wrapping.


Eligibility criteria:
inclusion criteria: * preterm infants \<29 weeks' gestation born in the study centers exclusion criteria: * congenital anomalies with open lesions (e.g. gastroschisis, meningomyelocele) and babies whose delivery was not attended by the neonatal team
mapping of metabolic liver functions in patients with non-alcoholic fatty liver disease

Conditions: Non-alcoholic Fatty Liver Disease

Summary: background: non-alcoholic fatty liver disease (nafld) is the most common cause of chronic liver disease in the western world and an important cause of morbidity and mortality including risk of cardiovascular disease. a ruling dogma is that a fatty liver is well-functioning. recent studies imply the contrary but quantitative measurements of metabolic liver function have not been systematically investigated in nafld. objectives: to study and quantify specific metabolic liver functions in varying degrees of nafld. furthermore to map the coagulation system of patients with nafld. methods: a human clinical study. metabolic liver functions are studied by a series of functional tests (galactose elimination capacity (gec), aminopyrine breath test (abt), indocyanine green plasma disappearance rate (icg-pdr), functional hepatic nitrogen clearance (fhnc)). regional liver function evaluated by 2-\[18f\]fluoro-2-deoxy-d-galactose (fdgal) pet/ct is compared to fat infiltration assessed by magnetic resonance imaging (mri). primary and secondary hemostasis, natural anti-coagulants and fibrinolysis are evaluated. perspectives: to challenge the dogma, that hepatic metabolic function is not affected in nafld, improving the understanding of the relationship between the clinical degree of nafld, histology, metabolic functions, and imaging. furthermore to disclose a proposed procoagulant imbalance in nafld.


Eligibility criteria:
inclusion criteria: * age ≥ 18 * hepatic steatosis found on ultrasound * clinical indication for liver biopsy (typically persistently elevated alanine transaminase (alt) levels) exclusion criteria: * other liver pathology * alcohol consumption \> 20g/day * chronic inflammatory disease, current infection or cancer * diabetes mellitus type i, ii or hba1c ≥ 48 mmol/mol (6.5 %) * prednisolone treatment within last 8 weeks * pregnancy within last 12 months * contraindication for mri

Keywords: liver function tests blood coagulation
a single-center evaluation of the relative efficacy of em-100 compared to zaditor® (ketotifen fumarate ophthalmic solution 0.035%) and vehicle

Conditions: Allergic Conjunctivitis

Summary: a single-center study to demonstrate the non-inferiority of em-100 to zaditor® in the treatment of ocular itching.


Eligibility criteria:
inclusion criteria: * be at least 18 years old * have a positive history of allergic conjunctivitis and positive skin test reaction to allergens * be willing to avoid disallowed medications for the appropriate washout period and throughout the trial * be willing to avoid contact lens use * be willing to have a pregnancy test * must be able to read an eye chart from 10 feet away exclusion criteria: * must not have any allergies to the study medications * must not have any ocular or non ocular condition that investigator feels will interfere with study parameters * must not have used an investigational drug or device in the past 30 days or currently be enrolled in another investigational trial
study of motexafin gadolinium and docetaxel for advanced solid tumors

Conditions: Breast Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Lung Neoplasms

Summary: the primary purpose of this study is to evaluate the safety, toxicities, and dosage for investigational drug motexafin gadolinium administered with docetaxel to patients with advanced solid tumors. secondly, tumor response to the combined treatment will be evaluated.


Eligibility criteria:
inclusion criteria: * ≥ 18 years old * histologically or cytologically confirmed diagnosis of cancer (i.e., unresectable locally advanced or metastatic non-small-cell lung carcinoma (nsclc) that had progressed during or after one or more chemotherapy regimens; metastatic breast cancer; hormone-refractory prostate cancer; recurrent or refractory ovarian cancer; sarcoma) * ecog performance status score either 0 or 1 * willing and able to provide written informed consent exclusion criteria: laboratory values of: * absolute neutrophil count \< 2000/µl * platelet count \< 100,00/µl * ast or alt \> 1.5 x the upper limit of normal * alkaline phosphatase \> 5 x the upper limit of normal * bilirubin \> uln * creatinine \> 2.0 mg/dl and * peripheral neuropathy nci ctc grade 3 or higher * chemotherapy, radiation therapy, immunotherapy, or systemic biologic * anticancer therapy within 21 days before beginning study treatment * known history of brain metastases or spinal cord compression * uncontrolled hypertension * myocardial infarction within 6 months before beginning study treatment * unstable angina pectoris, uncontrolled congestive heart failure, or uncontrolled serious arrhythmias * known sensitivity to or intolerable adverse effects from taxanes or polysorbate 80 * known history of porphyria (testing not required at screening) * known history of glucose-6-phosphate dehydrogenase (g6pd) deficiency (testing not required at screening) * known history of hiv infection (testing not required at screening) * female who is pregnant or lactating (pregnancy test is required for all female patients of childbearing potential) * female of childbearing potential or sexually active male unwilling to use adequate contraceptive protection * physical or mental condition that makes patient unable to complete specified follow-up assessments

Keywords: antineoplastic combined chemotherapy protocols
the effect of ischemic pre-conditioning on the rate of recovery following exercise-induced muscle damage

Conditions: Exercise-induced Muscle Damage

Summary: strenuous exercise or exercise involving eccentric muscle contractions can lead to muscle damage and changes in muscle function; this is known as exercise-induced muscle damage (eimd). it is known that brief, repeated periods of ischemia followed by reperfusion, known as ischemic preconditioning (ipc) cause a delay in cell injury in cardiac muscle as well as in various other organs. therefore the purpose of this study is to: 1. quantify the use of ipc in recovery following eimd. 2. identify any effect of ipc during recovery on muscle function


Eligibility criteria:
inclusion criteria: * physically active males exclusion criteria: * muscular skeletal disorders

Keywords: investigate ipc on eimd
a study to investigate if early atrial fibrillation (af) diagnosis reduces risk of events like stroke in the real-world

Conditions: Atrial Fibrillation

Summary: the primary objectives of this study are to identify and diagnose atrial fibrillation (af), evaluate improvement in cardiovascular (cv) outcomes, improve direct oral anti-coagulant (doac) adherence and persistence, and better characterize participants and identify predictors of disease.


Eligibility criteria:
inclusion criteria: * medicare beneficiary either with original or medicare advantage * authorize electronic access to their healthcare claims data * authorize sharing of device sensor, health, and heartline app data from their iphone and apple watch (if applicable). this includes apple watch and iphone sensor data that is not publicly available * willing and able to provide informed consent by electronically signing the remote e-consent directly in the heartline app prior to any study-related activities. electronically signing the remote e-consent indicates that he/she understands the purpose of, and activities required for the study and is willing to participate for the 2-year active engagement phase, with continued passive collection of their device and healthcare claims data for an additional 1 year in the post-engagement follow-up phase * current resident of the us at the time of eligibility screening, defined by self-reported state of residence within the 50 states or the us or district of columbia * own an iphone 6s or later with ios version 12.2 or later exclusion criteria: * limited life expectancy and/or current diagnosis of terminal cancer * unable to confirm meeting inclusion criteria, including ability to consent and participate in human participant's research * own an apple watch series 0 paired with an iphone at the time of screening eligibility (these participants are not eligible for any study cohorts \[randomized or observational\]) * have a confirmed diagnosis of atrial fibrillation (af) at study entry and currently taking a direct oral anti-coagulant (doac) for less than (\<) 30 days, currently taking other anti-coagulant medication(s) for af other than a doac, or currently not taking medication for af
effects of remodulin in patients with critical limb ischemia following a vein bypass graft

Conditions: Peripheral Vascular Disease

Summary: approximately 30 patients will be enrolled in this 12-week study designed to assess the effect of continuous subcutaneous remodulin therapy on the outcome of infrainguinal bypass grafts in patients with critical limb ischemia (cli). portions of the study will be conducted in the hospital and on an out-patient basis. the study will be conducted at multiple centers.


Eligibility criteria:
* patients with critical limb ischemia and an appropriate reference lower-limb ischemic wound due to documented peripheral arterial disease who have had an autogenous vein infrainguinal bypass graft performed immediately prior to study initiation.

Keywords: critical limb ischemia autogenous bypass graft cli